Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database

Louise Emmett[1–3], Nathan Papa[2], William Counter[1], Jeremie Calais[4], Francesco Barbato[5], Irene Burger[6], Matthias Eiber[7], Matthew J. Roberts[8], Shikha Agrawal[1,2], Anthony Franklin[8], Alan Xue[9], Krishan Rasiah[10], Nikeith John[1,3], Daniel Moon[11], Mark Frydenberg[9], John Yaxley[12], Phillip Stricker[13], Keith Wong[1], Geoff Coughlin[12], Troy Gianduzzo[12], Boon Kua[12], Bao Ho[1], Andrew Nguyen[1,3], Victor Liu[1], Jonathan Lee[1], Edward Hsiao[9], Tom Sutherland[15], Elisa Perry[15], Wolfgang P. Fendler[5], and Thomas A. Hope[16]

[1]Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital Sydney, Sydney, New South Wales, Australia; [2]Garvan Institute of Medical Research, Sydney, New South Wales, Australia; [3]St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia; [4]Ahmanson Translational Theranostics, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California; [5]Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital Essen, Essen, Germany; [6]Department of Nuclear Medicine, Kantonsspital Baden, Baden, Switzerland; [7]Department of Nuclear Medicine, School of Medicine, Technical University Munich, Munich, Germany; [8]Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; [9]Department of Surgery, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia; [10]Department of Urology, Royal North Shore Hospital, Sydney, New South Wales, Australia; [11]Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; [12]Wesley Hospital, Brisbane, Queensland, Australia; [13]St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia; [14]Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia; [15]Department of Radiology, St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia; and [16]Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California

The PRIMARY score is a 5-category scale developed to identify clinically significant intraprostate malignancy (csPCa) on ^{68}Ga-prostate-specific membrane antigen (PSMA)–11 PET/CT (^{68}Ga-PSMA PET) using a combination of anatomic site, pattern, and intensity. Developed within the PRIMARY trial, the score requires evaluation in external datasets. This study aimed to assess the reproducibility and diagnostic accuracy of the PRIMARY score in a cohort of patients who underwent multiparametric MRI (mpMRI) and ^{68}Ga-PSMA PET before prostate biopsy for the diagnosis of prostate cancer. **Methods:** In total, data from 242 men who had undergone ^{68}Ga-PSMA PET and mpMRI before transperineal prostate biopsy were available for this ethics-approved retrospective study. ^{68}Ga-PSMA PET and mpMRI data were centrally collated in a cloud-based deidentified image database. Six experienced prostate-focused nuclear medicine specialists were trained (1 h) in applying the PRIMARY score with 30 sample images. Six radiologists experienced in prostate mpMRI read images as per the Prostate Imaging–Reporting and Data System (PI-RADS), version 2.1. All images were read (with masking of clinical information) at least twice, with discordant findings sent to a masked third (or fourth) reader as necessary. Cohen κ was determined for both imaging scales as 5 categories and then collapsed to binary (negative and positive) categories (score 1 or 2 vs. 3, 4, or 5). Diagnostic performance parameters were calculated, with an International Society of Urological Pathology grade group of at least 2 (csPCa) on biopsy defined as the gold standard. Combined-imaging–positive results were defined as any PI-RADS score of 4 or 5 or as a PI-RADS score of 1–3 with a PRIMARY score of 3–5. **Results:** In total, 227 patients with histopathology, ^{68}Ga-PSMA PET, and mpMRI imaging before prostate biopsy were included; 33% had no csPCa, and 67% had csPCa. Overall interrater reliability was higher for the PRIMARY scale (κ = 0.70) than for PI-RADS (κ = 0.58) when assessed as a binary category (benign vs. malignant). This was similar for all 5 categories (κ = 0.65 vs. 0.48). Diagnostic performance to detect csPCa was comparable between PSMA PET and mpMRI (sensitivity, 86% vs. 89%; specificity, 76% vs. 74%; positive predictive value, 88% vs. 88%; negative predictive value, 72% vs. 76%). Using combined imaging, sensitivity was 94%, specificity was 68%, positive predictive value was 86%, and negative predictive value was 85%. **Conclusion:** The PRIMARY score applied by first-user nuclear medicine specialists showed substantial interrater reproducibility, exceeding that of PI-RADS applied by mpMRI-experienced radiologists. Diagnostic performance was similar between the 2 modalities. The PRIMARY score should be considered when interpreting intraprostatic PSMA PET images.

Key Words: multiparametric MRI; PSMA; prostate-specific membrane antigen; PET; prostate cancer; diagnosis

The diagnosis of clinically significant prostate cancer (csPCa) has improved with the introduction of imaging-targeted biopsy with multiparametric MRI (mpMRI), allowing a proportion of men with normal MRI results to avoid biopsy and allowing MRI-targeted biopsy, improving the diagnosis of high-grade malignancy (*1,2*). The addition of ^{68}Ga-prostate-specific membrane antigen (PSMA)–11 PET/CT (^{68}Ga-PSMA PET) to mpMRI further improved the negative predictive

FIGURE 1. Five-point PRIMARY score (4).

value for prostate cancer diagnosis in the PRIMARY trial (3,4). The primary objective of this study was to validate the PRIMARY score developed in the prospective PRIMARY trial using a dataset of retrospectively collected real-world patients undergoing ^{68}Ga-PSMA PET and mpMRI before prostate biopsy.

MATERIALS AND METHODS

This retrospective project was approved by the Human Research Ethics Board at St. Vincent's Hospital Sydney (approval 2022/ETH00051). Patients from investigating urologists in Australia who had undergone both ^{68}Ga-PSMA PET and mpMRI before initial prostate biopsy were identified. PSMA PET undertaken after biopsy for staging was an exclusion criterion. All patients had clinical data collected, including age, PSA level at the time of imaging, and the dates of imaging and biopsy procedures. The urologists' reasons for biopsy or imaging were not available. ^{68}Ga-PSMA PET and mpMRI were undertaken as per institutional protocols.

Imaging Data Collection

Both ^{68}Ga-PSMA PET and mpMRI data were centrally collated and deidentified on a secure web-based server (MIMcloud; MIM Software) for independent review, with imaging modalities collated into separated imaging datasets to ensure masked reads by imagers. All imaging and clinical data were collated on an institutional REDCap database (St. Vincent's Hospital Sydney) specifically designed for the

trial. Case report forms were developed to record both PRIMARY and Prostate Imaging–Reporting and Data System (PI-RADS) scores. The PRIMARY score was documented as previously defined, with 5 categories: score 1, no significant pattern within the prostate; score 2, a diffuse transition or central zone pattern; score 3, focal transition zone activity above twice the background transition zone counts; score 4, focal peripheral zone activity of any intensity; and score 5, an SUV of more than 12 (Fig. 1) (4).

Image Reads and Analysis

Deidentified ^{68}Ga-PSMA PET images were independently read by 6 ^{68}Ga-PSMA PET–experienced nuclear medicine physicians according to the PRIMARY score. Each scan was read by 2 readers, with a maximum of 40 scans read by the same 2 readers. To get a single ^{68}Ga-PSMA PET imaging decision per patient, any reader disagreement requiring a masked read by a third reader occurred when the first score was 1 or 2 and the second score was 3, 4, or 5. Before commencing, all nuclear medicine imaging investigators participated in a 1-h training session involving an explanation of the PRIMARY score and a consensus read of 30 ^{68}Ga-PSMA PET scans external to the study dataset. All readers were instructed to use the fused PET/CT images to allow differentiation between transition-zone and peripheral-zone activity. Images were read using the readers' preferred PET image viewer platform.

Six experienced prostate MRI radiologists read mpMRI images as per PI-RADS version 2.1 independently of the PSMA PET or clinical results (5). To get a single PI-RADS score per patient, in the event of disagreement on PI-RADS scores between 2 readers, a third masked

TABLE 1
Patient Characteristics (n = 227)

Characteristic	Data
Age (y)	68 (61–74)
PSA (ng/mL)	6.8 (4.8–10.3)
Days from MRI to biopsy	33 (14–79)
Days from PET to biopsy	15 (6–35)
Grade group	
No cancer	58 (26)
1	16 (7.0)
2	49 (22)
3	35 (15)
4	13 (5.7)
5	56 (25)
PI-RADS*	
1	2 (0.9)
2	70 (31)
3	26 (11)
4	56 (25)
5	73 (32)
PRIMARY[†]	
Negative (1,2)	78 (34)
Positive (3–5)	149 (66)

*Taken as majority score from at least 2 readers.
[†]Taken as majority read from 2 of 3 readers if discordant.
Qualitative data are number and percentage; continuous data are median and interquartile range.

FIGURE 2. Cohen κ-coefficient for PRIMARY and PI-RADS divided into 2 categories or left as 5 categories. Overall coefficient and 95% CI are presented as thicker symbols and lines, with pairwise interrater values presented next to these as thinner, fainter symbols and lines.

tie-breaking read was performed by another expert reader. If this was discordant with the other reads, a fourth read was undertaken.

Histopathology

Histopathology from biopsy was derived from the clinical histopathology report. Transperineal rather than transrectal ultrasound biopsy was undertaken in all cases. The median number of cores was 22. Systematic biopsy was standard, with MRI-guided additional cores also obtained in some cases. The International Society of Urological Pathology (ISUP) grade group reported for the trial was for the index lesion.

Statistical Analysis

The primary outcome of interest was an estimate of the interrater reliability of the PRIMARY score, in its original 5 categories and as a binary evaluation (score 1 or 2 vs. 3, 4, or 5), for nuclear medicine specialists new to using the score. This was measured using the Cohen κ-coefficient, with the interpretations of the value by Landis and Koch adopted in the figures and text (0–0.2 indicating slight agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, substantial agreement; and 0.81–1.0, almost perfect or perfect agreement). Additionally, the analogous analysis was performed for the mpMRI read with PI-RADS with the further evaluation for 3 categories of PI-RADS (1 or 2 vs. 3 vs. 4 or 5). The sample size per reader pair aimed to exceed the heuristic of 30 previously proposed in the literature (6). Further, we expected heterogeneity between PET reader pairs given the novelty of the scale. Combined with a convenience sample of about 240 patients, it was thus decided to invite 6 readers for each imaging modality. Secondary aims were, first, to calculate diagnostic accuracy for ⁶⁸Ga-PSMA PET using the PRIMARY score and for mpMRI using PI-RADS, with an ISUP grade group of 2 or more on biopsy being the gold standard; second, to calculate the diagnostic accuracy of a rational combination of imaging modalities based on the original PRIMARY paper (defining combined imaging positivity as PI-RADS 4/5 or PI-RADS 1–3 with a PRIMARY score of 3–5); third, to assess the distribution of ISUP grade group across categories of PI-RADS and binary PRIMARY score; and fourth, to evaluate the association between ISUP grade group and SUV_{max}, defined as the mean SUV_{max} reported by the 2 readers, with the Kruskal–Wallis test and significance set at a P value of less than 0.05. Stata version 17.0MP (StataCorp LLC) was used to generate the figures and analysis.

RESULTS

In total, 242 patients were available for analysis, having undergone ⁶⁸Ga-PSMA PET and mpMRI, no prior prostate biopsy or treatment for prostate cancer, and subsequent transperineal prostate biopsy. Five had no pathology data available, a further 8 had no MR images

available, and 2 more had no PET images available, leaving 227 patients for analysis (Table 1; Supplemental Fig. 1 [supplemental materials are available at http://jnm.snmjournals.org]). Seventy-four men (33%) did not have csPCa, 49 (22%) had ISUP grade group 2 disease, and 104 (46%) had ISUP grade group 3–5 disease.

Reproducibility

The overall κ for binary PRIMARY score categories (1 or 2 vs. 3, 4, or 5) was 0.70 (95% CI, 0.61–0.80), with a percentage agreement of 86% (Fig. 2). Pairwise κ-values ranged from 0.55 to 0.87. Interrater reliability for the full 5-category scale was substantial at 0.65 (95% CI, 0.58–0.73), percentage agreement was 74%, and pairwise κ-values ranged from 0.52 to 0.73. The overall κ for binary PI-RADS (1 or 2 vs. 3, 4, or 5) was moderate at 0.58 (95% CI, 0.46–0.70), with a percentage agreement of 82%. For a 3-group categorization of PI-RADS (1 or 2 vs. 3 vs. 4 or 5), the κ was 0.55 (95% CI, 0.46–0.65), with percentage agreement of 75%, and for the full 5-category scale, the κ was 0.48 (95% CI, 0.40–0.56), with percentage agreement of 61%. Twelve patients had discordant PI-RADS scores among 3 readers and required a fourth read. There were 7 pairs of MRI readers, instead of 6, as the allotment of 1 reader could not be completed (paired reader κ-values are shown in Supplemental Tables 1–5).

Diagnostic Accuracy

In total, 149 (66%) of patients had a positive ⁶⁸Ga-PSMA PET result (PRIMARY score of 3, 4, or 5), and 155 (68%) had a positive MRI result (PI-RADS score of 3, 4, or 5). The sensitivity of ⁶⁸Ga-PSMA PET was 86% (95% CI, 79%–91%), and the specificity was 76% (95% CI, 64%–85%), whereas the sensitivity of MRI was 89% (95% CI, 83%–93%), with a specificity of 74% (95% CI, 63%–84%). Individual PET and mpMRI reader sensitivities are represented in Figure 3. The positive predictive value for ⁶⁸Ga-PSMA PET was 88% (95% CI, 82%–93%), with a negative predictive value of 72% (95% CI, 61%–81%), and the respective


FIGURE 3. Sensitivity vs. (1 − specificity) overall for ⁶⁸Ga-PSMA PET and MRI derived from PRIMARY and PI-RADS scores, respectively. Faint markers and lines denote individual readers.

TABLE 2
Diagnostic Accuracy for PI-RADS, PRIMARY, and Combination

Parameter	Sensitivity	Specificity	Positive predictive value	Negative predictive value
PRIMARY	86% (79%–91%)	76% (64%–85%)	88% (82%–93%)	72% (61%–81%),
PI-RADS	89% (83%–93%)	74% (63%–84%)	88% (82%–93%	76% (65%–86%)
Combination	94% (89%–97%)	68% (56%–78%).	86% (80%–91%)	85% (73%–93%)

values for MRI were 88% (95% CI, 82%–93%) and 76% (95% CI, 65%–86%). Using the combined ^{68}Ga-PSMA PET/MRI definition of positive findings, the sensitivity was 94% (95% CI, 89%–97%), with a specificity of 68% (95% CI, 56%–78%). The positive predictive value was 86% (95% CI, 80%–91%), and the negative predictive value was 85% (95% CI, 73%–93%) (Table 2; Supplemental Table 6).

Histopathology and Imaging

The distribution of histology grade according to positive or negative ^{68}Ga-PSMA PET finding and category of PI-RADS is demonstrated in Figure 4. In each PI-RADS category, positive ^{68}Ga-PSMA PET results, versus negative, resulted in a higher percentage of csPCa and ISUP grade group 3–5 cancer. Five of 45 patients (11%) with a PI-RADS score of 1 or 2 and ^{68}Ga-PSMA PET–negative results had csPCa, all ISUP grade group 2. One patient of 59 (1.7%) had negative results on combined imaging (PI-RADS score of 3, ^{68}Ga-PSMA PET–negative) and ISUP grade group 5 disease (Fig. 5). This patient's MR images were read 3 times (PI-RADS scores of 2, 3, and 3), and the PET images were read twice (PRIMARY scores of 1 and 2).

SUV$_{max}$ and Grade Group

There was a statistically significant association between PSMA PET SUV$_{max}$, taken as the mean of 2 readers, and ISUP grade group ($P < 0.001$) (Fig. 6). All patients with an SUV$_{max}$ of more than 12 (PRIMARY score, 5) had csPCa, with 51 of 55 (93%) of those patients being ISUP grade group 3 or higher.

DISCUSSION

The PRIMARY score was developed to optimize the diagnostic accuracy of ^{68}Ga-PSMA PET for csPCa intraprostatically and

FIGURE 4. Cumulative percentage distribution of ISUP grade group by positive or negative ^{68}Ga-PSMA PET result and 3 categories of PI-RADS. GG = grade group.

particularly to improve specificity over an SUV$_{max}$-based reporting method (3,4). The PRIMARY score has been incorporated into PROMISE version 2 for reporting of ^{68}Ga-PSMA PET (7). This validation study undertaken on a real-world dataset confirmed the high diagnostic accuracy of the PRIMARY score, with significant reproducibility among readers. Accuracy was equivalent to the MRI PI-RADS score, with better reproducibility, despite the limited experience of the readers with the PRIMARY score.

Benign intraprostatic patterns of PSMA activity with increased uptake in the transition and central zones are common as a result of benign prostatic hypertrophy and physiologic activity surrounding the ejaculatory ducts in the central zones (8,9). However, most malignancy (70%) arises within the peripheral zone of the prostate, with the incidence of transition and central zone malignancy significantly lower (10). The PRIMARY score uses this information to weight focal activity in the peripheral and transition zones while classifying diffuse transition zone activity as a benign finding. The initial PRIMARY score publication found that separating patterns of intraprostatic PSMA activity into focal or diffuse improved identification of significant malignancy (4). This validation cohort confirmed improved specificity using a pattern-based reporting system rather than an intensity (SUV$_{max}$)-based analysis as was used in the initial PRIMARY paper (3).

mpMRI is now the standard of care for the diagnosis of csPCa, with key randomized trials demonstrating improved accuracy and a reduced requirement for biopsy compared with a non–imaging-based transrectal ultrasound biopsy diagnostic paradigm (2,11). However, despite better targeting with MRI, a significant number of malignancies are missed using an MRI-targeted approach, with a high proportion of negative biopsies that could potentially have been avoided (1). ^{68}Ga-PSMA PET using the PRIMARY score in conjunction with mpMRI may further optimize the diagnosis of prostate cancer, reducing the biopsy requirement and detection of insignificant malignancy while improving sensitivity for csPCa. This is being evaluated further in the prospective randomized PRIMARY2 trial (NCT05154162).

There is a strong association between ISUP grade group on histopathology and ^{68}Ga-PSMA PET intensity, an association that is likely due to the pro-proliferative role of the PSMA receptor in prostate cancer (12–16). As with the PRIMARY study, the analysis found that an SUV$_{max}$ of more than 12 was associated with csPCa in 100%, with an ISUP grade group of at least 3 in 93% of those cases. This finding validates the use of PSMA intensity (SUV$_{max}$ > 12) as the maximal PRIMARY score, although further work will be required to identify an optimum intensity for a PRIMARY score of 5 if PSMA-targeting peptides other than ^{68}Ga-PSMA are to be utilized.

The Cohen κ demonstrated substantial agreement between the 6 PRIMARY score readers in the study, despite the fact that training was limited to a single 1-h session and despite the lack of harmonization between PET cameras, acquisition protocols, and doses

FIGURE 5. PSMA PET imaging for patient with ISUP grade group 5 on histopathology, negative result on ^{68}Ga-PSMA PET central read, and PI-RADS 3 on MRI. Central readers had 1-h training session on PRIMARY score with little prior exposure, and this lesion was missed by both readers. This image is technically PRIMARY score 4 (arrows) with focal lesion apically (SUV$_{max}$, 3.5).

due to the retrospective nature of the study. There was a single ISUP grade group 5 classified as PSMA-negative by both central readers and with equivocal mpMRI results (PI-RADS score, 3). This scan had focal PSMA avidity apically, fulfilling the criteria for a PRIMARY score of 4. It is expected that the reported diagnostic accuracy of the PRIMARY score will improve with further training of readers. There was a lower κ-score for PI-RADS despite the readers' being high-volume prostate MRI specialists, pointing to reproducibility and simplicity as strengths of the PRIMARY score.

There are important limitations to the study. The study was designed as a real-world dataset to externally evaluate the findings of the PRIMARY trial. As such, it was retrospectively collected, and the reasons for which the urologists requested ^{68}Ga-PSMA PET before biopsy were not documented and will have introduced a selection bias, particularly for the PI-RADS 1 and 2 patients included. Also because of the retrospective design, no camera or dose harmonization was possible. Nevertheless, the results show diagnostic accuracy similar to that of the prospective PRIMARY trial, demonstrating the reproducibility of the score, both for accuracy and among readers. A higher proportion of patients had more aggressive disease on histopathology than in the PRIMARY trial,

with a lower proportion of benign or low-grade findings. This factor may have impacted the negative predictive value of the PRIMARY, PI-RADS, and combination scores. In the evaluation of reader agreement for both MRI and PSMA, the study utilized 2 readers—with a third reader for discordance—rather than the 3 readers considered optimal in a registration study (*17*).

Both the PRIMARY trial and this validation study utilized ^{68}Ga-PSMA PET. Although it is likely that the PRIMARY score is translatable to other PSMA PET agents given the focus on pattern and anatomic site, this possibility requires further evaluation.

CONCLUSION

The PRIMARY score showed substantial interrater reproducibility by first-user nuclear medicine specialists, exceeding that of PI-RADS. Diagnostic performance was similar between the 2 modalities. The PRIMARY score should be considered when interpreting intraprostatic PSMA PET images.

FIGURE 6. Horizontal box plot of SUV$_{max}$ by ISUP grade group, taken as mean of 2 readers' reports. Not shown are 1 ISUP grade group 3 lesion (SUV$_{max}$, 62) and 2 ISUP grade group 5 lesions (SUV$_{max}$, 44 and 46).

KEY POINTS

QUESTION: Is the PRIMARY score an accurate reproducible method for reporting intraprostatic PSMA PET findings in men prior to prostate biopsy, and how does it compare to mpMRI?

PERTINENT FINDINGS: The PRIMARY score is equivalent in diagnostic accuracy to mpMRI when undertaken prior to prostate biopsy in a high-risk population. Further, it is more reproducible than mpMRI despite the readers having limited clinical experience with the score.

IMPLICATIONS FOR PATIENT CARE: A 5-level PRIMARY score incorporating intraprostatic patterns and intensity on ^{68}Ga-PSMA PET/CT shows potential as an accurate method for diagnosing csPCa and should be considered when PSMA PET is undertaken for this purpose.

REFERENCES

1. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet.* 2017;389:815–822.

2. Kasivisvanathan V, Emberton M, Moore CM. MRI-targeted biopsy for prostate-cancer diagnosis. *N Engl J Med.* 2018;379:589–590.

3. Emmett L, Buteau J, Papa N, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. *Eur Urol.* 2021;80:682–689.

4. Emmett L, Papa N, Buteau J, et al. The PRIMARY score: using intraprostatic ^{68}Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis. *J Nucl Med.* 2022;63:1644–1650.

5. Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J; Prostate Imaging–Reporting and Data System Steering Committee. PI-RADS v2 status update and future directions. *Eur Urol.* 2019;75:385–396.

6. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb).* 2012;22:276–282.

7. Seifert R, Emmett L, Rowe SP, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). *Eur Urol.* 2023;83:405–412.

8. Ganeshalingam R, Hsiao E. Compressed central zone uptake on PSMA PET/CT: a potential pitfall in interpretation. *Clin Nucl Med.* 2019;44:570–571.

9. Pizzuto DA, Müller J, Mühlematter U, et al. The central zone has increased ^{68}Ga-PSMA-11 uptake: "Mickey Mouse ears" can be hot on ^{68}Ga-PSMA-11 PET. *Eur J Nucl Med Mol Imaging.* 2018;45:1335–1343.

10. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. *Am J Surg Pathol.* 1988;12:897–906.

11. Sathianathen NJ, Omer A, Harriss E, et al. Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the Prostate Imaging Reporting and Data System era: a systematic review and meta-analysis. *Eur Urol.* 2020;78:402–414.

12. Caromile LA, Shapiro LH. PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression. *Mol Cell Oncol.* 2017;4:e1321168.

13. Eiber M, Nekolla SG, Maurer T, et al. ^{68}Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. *Abdom Imaging.* 2015;40:1769–1771.

14. Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. *J Exp Med.* 2018;215:159–175.

15. Roberts MJ, Morton A, Papa N, et al. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. *Eur J Nucl Med Mol Imaging.* 2022;49:3289–3294.

16. Scheltema MJ, Chang JI, Stricker PD, et al. Diagnostic accuracy of ^{68}Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of ^{68}Ga-PSMA PET to mpMRI. *BJU Int.* 2019;124(suppl 1):42–49.

17. Fendler WP, Calais J, Eiber M, et al. Assessment of ^{68}Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. *JAMA Oncol.* 2019;5:856–863.